In a report released today, Catherine Schulte from Robert W. Baird reiterated a Buy rating on PerkinElmer (NYSE: PKI), with a price target of $89. The company’s shares opened today at $81.55.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 26.0% and a 79.2% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Oxford Immunotec, NanoString Tech, and Exact Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PerkinElmer with a $87 average price target.
See today’s analyst top recommended stocks >>
PerkinElmer’s market cap is currently $8.84B and has a P/E ratio of 83.70. The company has a Price to Book ratio of 3.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PerkinElmer, Inc. (United States) engages in the provision of products, services, and solutions to diagnostics, food, environmental, industrial, life sciences research, and laboratory services markets. It operates through the Discovery and Analytical Solutions, and Diagnostics segments.
